ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Helsinn launches venture fund

by Ann M. Thayer
October 17, 2016 | APPEARED IN VOLUME 94, ISSUE 41

The Swiss drug firm Helsinn has started a $50 million venture capital fund to invest in drug, device, and food start-ups. The fund will support firms with early-stage technologies for cancer therapeutics, diagnostics, and supportive care; metabolic and gastrointestinal disorders; and dermatology conditions. Helsinn will invest in 10 to 15 firms, providing scientific and clinical strategy guidance, along with operational and board support. So far, the fund has invested in firms including MEI Pharma, OncoResponse, and QuantuMDx.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment